Disease relevance of TSGA10

• In malignant tissues, TSGA10 was over-expressed in 4 of 20 hepatocellular carcinomas (HCC), 1 of 20 colon cancers, 7 of 20 ovarian cancers, 3 of 20 prostate cancers, 1 of 21 malignant melanomas, and 8 of 21 bladder cancers [1].
• CONCLUSIONS: TSGA10 is a new tumour-associated antigen of cutaneous lymphoma [2].
• Identification of the testis-specific protein 10 (TSGA10) as serologically defined tumour-associated antigen in primary cutaneous T-cell lymphoma [2].
• RESULTS: The testis-specific protein 10 (TSGA10) was identified as an antigen recognized by sera of two patients with Mycosis fungoides but not by sera from healthy donors [2].
• Expression of the testis-specific gene, TSGA10, in Iranian patients with acute lymphoblastic leukemia (ALL) [3].

High impact information on TSGA10

• Identification and characterisation of a novel gene, TSGA10, expressed in testis [4].
• By reverse transcription-polymerase chain reaction analysis, TSGA10 was found expressed in all cutaneous lymphoma samples tested, various tumour cell lines, testis, peripheral blood mononuclear cells, skin, isolated lymphocytes, keratinocytes and fibroblasts [2].
• We previously demonstrated TSGA10 expression during spermatogenesis [3].
• There is also evidence for potential TSGA10 involvement in cell proliferation [3].
• Here we demonstrated expression of TSGA10 by semi-quantitative RT-PCR in 44 (84.6%) out of 52 bone marrow samples and all peripheral blood samples from patients with acute lymphoblastic leukemia (ALL) [3].

Biological context of TSGA10

• TSGA10 is located on chromosome 2q11.2 and consists of 19 exons extending over 3 kb [1].

Analytical, diagnostic and therapeutic context of TSGA10

• TSGA10 mRNA expression was investigated in normal and malignant tissues using quantitative real-time RT-PCR [1].
• RT-PCR of TSGA10 may help in detection of residual clonal cells leading to early diagnosis and better prognostic qualification of the disease [3].
• Testis-specific gene antigen (TSGA10) is expressed in fetus, testis and frequently in human solid cancers and acute leukemias, making it a candidate for immunotherapy and for detection of minimal residual disease (MRD) [3].

References